

Still got style.
Still got strength.
Still got spirit.

Still
got
it.

I'm Debbie, and I don't let Parkinson's define me. That's because I take RYTARY, which gives me less "off" time and more time to do what I love.

If "off" time is defining your time, **RYTARY** may be able to help.

INDICATION

RYTARY (carbidopa and levodopa) extended-release capsules is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease like symptoms that may result from carbon monoxide or manganese poisoning.

IMPORTANT SAFETY INFORMATION

Do not take RYTARY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within two weeks of each other can result in high blood pressure.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

You may have Parkinson's, but you're still you.

We're all defined by something—

our character, a career, or even a cause. It's what we're known for, what keeps us going, and what makes us who we are.

Whatever it is that defines or drives you, don't let "off" time get in the way. Use the information found in this brochure to advocate for yourself, ask questions, and be honest about what you need from treatment. In doing so, you may be able to enjoy more of what makes you, you.

Caring for someone with Parkinson's?

Educate yourself with the information on the following pages and then partner with your loved one to answer the questions on page 12. By working together, you can find a treatment that lets you get back to doing more of what you enjoy.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.



“ I believe in trying anything I can to make myself better. I won't settle for feeling bad. It's important for those of us with Parkinson's to be proactive, to speak up, and to be our own advocates. ”

Daran
ON RYTARY
SINCE 2015

RYTARY[®]
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

The individuals appearing in this piece were sponsored by Amneal Pharmaceuticals. Your experience and results may vary.

If you're having "off" time, RYTARY may be able to help.

Whether you've been living with Parkinson's for a while, were recently diagnosed, or are caring for someone with the disease, you're probably familiar with the terms "on" time and "off" time.

"On" time – when symptoms are under control

"Off" time – when symptoms occur

Often, "off" time is caused by one's Parkinson's medication, not the medical condition. For example, immediate-release carbidopa/levodopa (IR CD/LD)—a common Parkinson's medication—works quickly, but usually doesn't last very long. And when it stops working, "off" time occurs.

RYTARY, on the other hand—also a CD/LD medication—is uniquely formulated to be both immediate *and* extended release. Meaning that each dose lasts longer than other CD/LD medications.

If you're having "off" time, let your doctor know. You may also want to bring a loved one to the appointment, as they'll be able to provide an additional perspective on how "off" time affects your life.

IMPORTANT SAFETY INFORMATION (continued)

Taking RYTARY may result in falling asleep while engaged in normal activities, even without warning and as late as one year after starting RYTARY. This may affect your ability to drive or operate machinery. Do not do anything that requires alertness until you know how RYTARY affects you.



“ During an office visit in 2015, my doctor told me about a product called RYTARY, that's an extended release carbidopa/levodopa. She said, 'I think we should try it. It helps reduce Parkinson's motor symptoms.' I was all for that! ”

Individual results may vary.

Debbie
ON RYTARY
SINCE 2015

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.


RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

With RYTARY, it's all about the beads.

Unlike IR CD/LD, each RYTARY capsule contains a unique combination of time-release beads.

1/3 of the beads are immediate release, which allow RYTARY to start delivering medication at about 1 hour

2/3 of the beads are extended release, which, when combined with the other beads, allow RYTARY to sustain medication levels for up to 4–5 hours




IMPORTANT SAFETY INFORMATION (continued)

Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking), if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if abnormal involuntary movements appear or get worse during treatment with RYTARY; or if you have ever had a peptic ulcer or glaucoma.

RYTARY lasts longer than other CD/LD treatments.

Most CD/LD treatments are unable to keep medication levels steady in the body. Which means people who take them may fluctuate frequently between periods of “on” and “off” time.

However, when a study compared RYTARY to other CD/LD treatments, **RYTARY sustained medication levels for up to ~5 hours, outlasting Sinemet®, Sinemet® CR, and Stalevo®.**



Sinemet® lasted	Sinemet® CR lasted	Stalevo® lasted	RYTARY lasted
~1.5 hours	~2 hours	~2 hours	~5 hours

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY®
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

RYTARY can help the real you shine through.

In another clinical study, the effectiveness of RYTARY was compared to IR CD/LD in people with advanced Parkinson's disease. In this study, RYTARY demonstrated:

2X reduction in "off" time during waking hours

- 13.1% reduction vs 6.2% reduction with IR CD/LD
- 2.2 hours vs 1 hour with IR CD/LD*

2X increase in "on" time without troublesome dyskinesia

- 1.8 hours vs 0.8 hours with IR CD/LD*

Better movement control

- Improved performance of motor functions and activities of daily living*

*These were secondary measures in the study.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects that may occur with RYTARY include nausea, dizziness, headache, sleeplessness, abnormal dreams, dry mouth, abnormal involuntary movements, anxiety, constipation, vomiting, and low blood pressure upon rising.



“As my doctor and I had hoped, the timed-release features of RYTARY do afford me more effective coverage and more ‘on’ time where my tremor is controlled. That’s really important to me, especially when I’m giving presentations at work or playing sports with my friends.”

Individual results may vary.

Phil
ON RYTARY
SINCE 2015


Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

RYTARY provides more “on” time with each dose.

A different analysis of the same study compared how many more hours of “on” time people get with each dose of RYTARY vs each dose of IR CD/LD.

The study found that RYTARY gave people 1.2 more hours of “on” time per dose than IR CD/LD.



*Hours of “on” time per dose at baseline and study end: 2.17 and 3.55 with RYTARY vs 2.24 and 2.38 with IR CD/LD ($P < 0.0001$).

People taking RYTARY also experienced 1.2 more hours per dose of “on” time **without troublesome dyskinesia** vs IR CD/LD.†

†Hours of “on” time per dose at baseline and study end: 2.10 and 3.41 with RYTARY vs 2.17 and 2.29 with IR CD/LD ($P < 0.0001$).

IMPORTANT SAFETY INFORMATION (continued)

Some patients taking RYTARY have experienced suicidal thoughts or have attempted suicide. Tell your healthcare provider if you have thoughts of suicide or have attempted suicide.



“Helping others has been an important part of my life and, in turn, it’s been a big part of my experience with Parkinson’s. With my ‘on’ time, I can focus on my volunteer work.”

Pat
ON RYTARY
SINCE 2015

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

Is it time for RYTARY?

Consider the information you've learned so far, and then ask yourself the following questions. If you're a care partner, sit down with your loved one and answer these questions together. If you answer "yes" to one or more of them, it may be time to ask your doctor about RYTARY.

	Yes	No	Not Sure
Is it hard to predict how the day will go because of "off" time?			
Is Parkinson's getting in the way of making plans or doing everyday activities?			
Could I/my loved one benefit from a treatment option that lasts longer than other CD/LD medications?			

IMPORTANT SAFETY INFORMATION (continued)

Notify your healthcare provider if you become pregnant or intend to become pregnant during therapy or if you intend to breast-feed or are breast-feeding an infant.

Learn more about RYTARY from an expert.

And then talk to your own doctor about your options.

“ One of the most commonly asked questions I hear from my patients starting RYTARY is why I think it's an appropriate treatment for them. ”



Drew Falconer, MD
 Director, Movement Disorders Specialist
 Inova Parkinson's and Movement Disorders Center
 Alexandria, Virginia



To hear why Movement Disorder Specialist Dr Drew Falconer prescribes RYTARY to his patients, hover your smartphone's camera over this QR code or visit RYTARY.com.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information.

RYTARY[®]
 (carbidopa and levodopa)
 EXTENDED-RELEASE CAPSULES
 23.75 mg/95 mg • 36.25 mg/145 mg
 48.75 mg/195 mg • 61.25 mg/245 mg

Get the support you need with BlinkRx



BlinkRx makes getting your RYTARY (carbidopa and levodopa) extended-release capsules simple. From finding all eligible savings to free delivery, and so much more.

Once your healthcare provider sends your RYTARY prescription to BlinkRx, the benefits begin. Here's how:



Step 1: BlinkRx will contact you. When your healthcare provider sends your prescription to BlinkRx, one of their agents will contact you. You can also contact BlinkRx directly at 833-984-2820.



Step 2: Check out online. BlinkRx works with your insurance to apply all eligible savings to your co-pay. When it's time to check out you can pay online or by phone, and you can also sign up for automatic refills.



Step 3: RYTARY is delivered to your home. With BlinkRx, delivery is always free and a signature is not required. BlinkRx provides tracking status so you always know the status of your deliveries.

You may receive free medication for 30 days with prescriptions filled through BlinkRx: **Contact BlinkRx at 833-984-2820**
RYTARY is also available at your local pharmacy.



IMPORTANT SAFETY INFORMATION (continued)

Talk to your healthcare provider before you lower the dose or stop taking RYTARY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.

Take RYTARY as instructed. You may take RYTARY with or without food; however, taking RYTARY with food may decrease or delay its effect. For this reason, consider taking the first dose of the day about 1 to 2 hours before eating. Swallow RYTARY whole; do not chew, divide, or crush. If you have difficulty swallowing the capsule, twist apart both halves and sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons). Consume the mixture immediately. Do not store the drug/food mixture for future use.

Note: This information is intended to aid in the safe and effective use of RYTARY. It is not a disclosure of all possible adverse or intended effects. Tell your healthcare provider if you have any side effects while taking RYTARY. He or she can make adjustments that may reduce these effects.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on adjacent pages and accompanying full Prescribing Information. For more information go to RYTARY.com and/or talk to your healthcare provider.

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg



Meet Denise. She's been on RYTARY since 2016.

To watch her real RYTARY story—and stories from others just like her—simply hover your smartphone's camera over this QR code, or visit [RYTARY.com](https://www.RYTARY.com).



Please see Important Safety Information on adjacent pages and accompanying full Prescribing Information.



RYTARY® is a registered trademark of Amneal Pharmaceuticals LLC.
© 2023 Amneal Pharmaceuticals LLC. Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
All rights reserved. Printed in USA. PP-PAT-RYT-US-0279-A-V2 03/2023

RYTARY[®]
(carbidopa and levodopa)

EXTENDED-RELEASE CAPSULES

23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg